menu search

UTHR / United Therapeutics Corporation to Present at the Cowen 42nd Annual Health Care Conference

United Therapeutics Corporation to Present at the Cowen 42nd Annual Health Care Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company's business during a fireside chat session at the Cowen 42nd Annual Health Care Conference. The session will take place virtually on Tuesday, March 8, 2022, from 11:10 a.m. to 11:40 a.m., Eastern Standard Time, and can be accessed via a live webcast on th Read More
Posted: Mar 1 2022, 06:00
Author Name: Business Wire
Views: 111594

UTHR News  

United Therapeutics Corporation (UTHR) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

United Therapeutics Corporation (UTHR) Q3 2023 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Dewey Steadman – He more_horizontal

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

By Zacks Investment Research
November 1, 2023

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

By Zacks Investment Research
November 1, 2023

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.38 per share, beating the Zacks Consensus Estimate of $4.89 per share. This compares more_horizontal

United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision

By Seeking Alpha
October 22, 2023

United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision

United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a com more_horizontal

United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

By Seeking Alpha
August 3, 2023

United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

United Therapeutics Corporation (NASDAQ: UTHR) reported strong quarterly results, adding strength to its economic characteristics. The company's finan more_horizontal

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it co more_horizontal

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.24 per share, beating the Zacks Consensus Estimate of $4.41 per share. This compares more_horizontal


Search within

Pages Search Results: